Current status of bortezomib in the treatment of multiple myeloma

被引：8

作者：

Cavo M. ^{[1
]}

机构：

[1] Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, 40138, Bologna

来源：

Current Hematologic Malignancy Reports | 2007年 / 2卷 / 2期

关键词：

Multiple Myeloma; Thalidomide; Bortezomib; Myeloma Cell; Lenalidomide;

D O I：

10.1007/s11899-007-0018-y

中图分类号：

学科分类号：

摘要：

Bortezomib (formerly PS-341) has been the first proteasome inhibitor to enter clinical trials in cancer patients. Preclinical studies showing that this novel agent directly inhibits the proliferation of myeloma cells, induces their apoptosis, and abrogates paracrine tumor growth through alteration of interactions of myeloma and stromal cells and through nuclear factor κB-dependent cytokine secretion prompted the design of large phase II and III studies of bortezomib in patients with advanced relapsed and/or refractory multiple myeloma. Favorable results of these studies led to accelerated approval for use of bortezomib in patients with multiple myeloma who have progressed after at least their second therapy and, more recently, to expanded approval for second-line use in patients in whom one prior therapy has failed. Combination studies of bortezomib with various agents, including dexamethasone, DNA-damaging drugs (such as melphalan, cyclophosphamide, and doxorubicin), thalidomide, and lenalidomide, are currently ongoing in patients with both relapsed/refractory and newly diagnosed disease. Bortezomib may be the backbone" for the development of more effective treatment strategies to improve patient outcome in multiple myeloma. Copyright © 2007 by Current Medicine Group LLC."

引用

页码：128 / 137

页数：9

共 46 条

[41] Cavo M., Zamagni E., Tosi P., Et al., Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma, Blood, 106, pp. 35-39, (2005)
[42] Rajkumar S.V., Blood E., Vesole D., Et al., Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group, J Clin Oncol, 24, pp. 431-436, (2006)
[43] Rajkumar S.V., Hayman S.R., Lacy M.Q., Et al., Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma, Blood, 106, pp. 4050-4053, (2005)
[44] Orlowski R.Z., Voorhees P.M., Garcia R.A., Et al., Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies, Blood, 105, pp. 3058-3065, (2005)
[45] Chanan-Khan A., Miller K.C., McCarthy P., A phase II study of Velcade (V), Doxil (D) in combination with low-dose thalidomide (T) as salvage therapy for patients with relapsed or refractory multiple myeloma (MM) and Waldenstrom's macroglobulinemia: Encouraging preliminary results [abstract], Blood (ASH Annual Meeting Abstracts), 104, (2004)
[46] Peles S., Fisher N.M., Devine S.M., Et al., Bortezomib (Velcade) when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV) [abstract], Blood (ASH Annual Meeting Abstracts), 106, (2005)

← 1 2 3 4 5 →